U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. Exela Pharma Sciences LLC - 611316 - 04/30/2021
  1. Warning Letters

CLOSEOUT LETTER

Exela Pharma Sciences LLC MARCS-CMS 611316 —

Delivery Method:
VIA Electronic Mail
Product:
Drugs
Recipient:
Recipient Name
Phanesh Koneru, Ph.D., LL.M.
Recipient Title
President & CEO
Exela Pharma Sciences LLC

1245 Blowing Rock Blvd.
Lenoir, NC 28645
United States

Issuing Office:
Office of Pharmaceutical Quality Operations, Division II

United States

Dear Dr. Koneru:

The U.S. Food and Drug Administration (FDA) has completed an evaluation of your firm’s corrective actions in response to our warning letter [Case #: 611316; Date: April 8, 2021]. Based on our evaluation, it appears that you have adequately addressed the violations contained in this warning letter. We acknowledge your firm’s intent to discontinue your 503B program, as stated in your warning letter response.

You are expected to take all necessary steps to ensure compliance with the Federal Food, Drug, and Cosmetic Act and FDA’s implementing regulations. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.

Sincerely,
Digitally signed by Dayna I. Martinez -S
DN: c=US, o=U.S. Government, ou=HHS, ou=FDA, ou=People, 0.9.2342.19200300.100.1.1=2000369349,
cn=Dayna I. Martinez -S
Date: 2021.04.30 12:20:09 -04'00'
Dayna Martinez
Acting Director, Compliance Branch
Office of Pharmaceutical Quality Operations, Division II

Back to Top